ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2019
Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.
Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- NETest2.0Cancers · 2026Article
- Clinicopathological and molecular determinants of pancreatic neuroendocrine tumors: toward precision risk stratification.Journal of translational medicine · 2026Review
- Circulating Tumor DNA Monitoring in Peptide Receptor Radionuclide Therapy-Treated Patients With Gastroenteropancreatic Neuroendocrine Tumors.JCO precision oncology · 2026Article
- Biomarker-directed aptamer panels for diagnosis and differentiation of neuroendocrine tumors.Journal of neuroendocrinology · 2026Article
- Differential diagnosis and predictive markers of pancreatic neuroendocrine tumours (PanNET).Virchows Archiv : an international journal of pathology · 2026Review
- From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms.Annals of medicine · 2025Review
- Article
- Prognostic Impact of Phenotypic and Genetic Features of Pancreatic Malignancies.Life (Basel, Switzerland) · 2025Review
- Basic science and translational implications of current knowledge on neuroendocrine tumors.The Journal of clinical investigation · 2025Review
- SCG2 and CPE may be novel markers for the identification of pancreatic neuroendocrine tumors and solid pseudopapillary neoplasms.Translational cancer research · 2024Article
- Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms.Journal of clinical medicine · 2023Review
- Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression.The Journal of clinical endocrinology and metabolism · 2023Article
- An Overview of Pancreatic Neuroendocrine Tumors and an Update on Endoscopic Techniques for Their Management.Current oncology (Toronto, Ont.) · 2023Review
- Radiomics Combined with Multiple Machine Learning Algorithms in Differentiating Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor: More Hands Produce a Stronger Flame.Journal of clinical medicine · 2022Article
- Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors.Journal of neuroendocrinology · 2022Article
- Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors.Journal of endocrinological investigation · 2022Article
- Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise.Cancers · 2022Article
- Prognostic significance of AP-2α/γ targets as cancer therapeutics.Scientific reports · 2022Article
- Review
- What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSerum Chromogranin A (CgA) is widely used as a biomarker for pancreatic neuroendocrine tumors (PanNETs). The aim of this study was to investigate the value of CgA as a diagnostic and prognostic marker for well-differentiated PanNETs.
methodsPatients with well-differentiated PanNET and a baseline CgA measurement, between 2011 and 2016 were reviewed. The diagnostic value was determined by comparing CgA values from patients with PanNETs to those with other pancreatic neoplasms and healthy controls. The Kaplan-Meier method was used to investigate the CgA prognostic significance.
resultsNinety-nine patients met inclusion criteria. As a diagnostic marker, CgA had a sensitivity of 66%, specificity of 95%, and overall accuracy of 71%. The use of PPIs was associated with a higher CgA level (p = 0.015). When excluding patients on PPIs, CgA accuracy in distinguishing PanNETs from other pancreatic neoplasms was 66%, the sensitivity and specificity were 60% and 75% respectively. Elevated CgA (p = 0.004), Ki67% (p < 0.001), tumor grade (p < 0.001) and stage of disease (p = 0.036) were associated with disease-specific survival.
conclusionCgA has a limited role as a diagnostic biomarker for well-differentiated PanNETs. An elevated CgA level may have prognostic value but its role should be further investigated with respect to other known pathological factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.